$CTKB
Cytek Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000162828024045834 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $51.50M
YoY Change 7.29%
Cost Of Revenue $22.50M
YoY Change 8.03%
Gross Profit $29.01M
YoY Change 6.72%
Gross Profit Margin 56.32%
Selling, General & Admin $23.37M
YoY Change 4.21%
% of Gross Profit 80.58%
Research & Development $9.882M
YoY Change -11.54%
% of Gross Profit 34.07%
Depreciation & Amortization $900.0K
YoY Change 0.0%
% of Gross Profit 3.1%
Operating Expenses $33.25M
YoY Change -1.03%
Operating Profit -$4.248M
YoY Change -33.83%
Interest Expense $1.314M
YoY Change 120.84%
% of Operating Profit
Other Income/Expense, Net $4.405M
YoY Change 97.09%
Pretax Income $157.0K
YoY Change -103.75%
Income Tax -$800.0K
% Of Pretax Income -509.55%
Net Earnings $941.0K
YoY Change -114.58%
Net Earnings / Revenue 1.83%
Basic Earnings Per Share
Diluted Earnings Per Share $0.01
COMMON SHARES
Basic Shares Outstanding 128.8M shares 131.5M shares
Diluted Shares Outstanding 132.8M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $277.8M
YoY Change -3.55%
Cash & Equivalents $162.3M
Short-Term Investments $115.5M
Other Short-Term Assets $2.341M
YoY Change 4.04%
Inventory $46.80M
Prepaid Expenses
Receivables $52.63M
Other Receivables
Total Short-Term Assets $390.2M
YoY Change -7.61%
LONG-TERM ASSETS
Property, Plant & Equipment $18.51M
YoY Change 6.28%
Goodwill $16.18M
YoY Change -1.66%
Intangibles $20.49M
YoY Change -15.64%
Long-Term Investments $1.600M
YoY Change 0.0%
Other Assets $4.950M
YoY Change 56.25%
Total Long-Term Assets $101.0M
YoY Change 4.04%
TOTAL ASSETS
Total Short-Term Assets $390.2M
Total Long-Term Assets $101.0M
Total Assets $491.2M
YoY Change -5.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $20.73M
YoY Change 1.07%
Deferred Revenue $40.15M
YoY Change 5.65%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.80M
YoY Change 6.99%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $2.121M
YoY Change -7.18%
Total Long-Term Liabilities $2.121M
YoY Change -7.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.80M
Total Long-Term Liabilities $2.121M
Total Liabilities $105.8M
YoY Change 1.79%
SHAREHOLDERS EQUITY
Retained Earnings -$44.84M
YoY Change 29.29%
Common Stock $130.0K
YoY Change -4.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $385.5M
YoY Change
Total Liabilities & Shareholders Equity $491.2M
YoY Change -5.43%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $941.0K
YoY Change -114.58%
Depreciation, Depletion And Amortization $900.0K
YoY Change 0.0%
Cash From Operating Activities $13.22M
YoY Change -411.82%
INVESTING ACTIVITIES
Capital Expenditures $1.003M
YoY Change -28.36%
Acquisitions
YoY Change
Other Investing Activities -$14.81M
YoY Change -133.26%
Cash From Investing Activities -$15.81M
YoY Change -136.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.08M
YoY Change 45.94%
NET CHANGE
Cash From Operating Activities 13.22M
Cash From Investing Activities -15.81M
Cash From Financing Activities -12.08M
Net Change In Cash -14.67M
YoY Change -147.95%
FREE CASH FLOW
Cash From Operating Activities $13.22M
Capital Expenditures $1.003M
Free Cash Flow $12.22M
YoY Change -316.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001831915
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
CYTEK BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2547526
dei Entity Address Address Line1
EntityAddressAddressLine1
47215 Lakeview Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
922-9835
dei Trading Symbol
TradingSymbol
CTKB
CY2024Q3 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
30778000 usd
CY2023Q4 us-gaap Assets
Assets
494457000 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5389000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3032000 usd
CY2024Q3 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
2496000 usd
CY2023Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
2561000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20733000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20035000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8814000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7903000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25365000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22695000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
62797000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56226000 usd
CY2024Q3 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
17066000 usd
CY2023Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
16477000 usd
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14787000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7756000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9479000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1236000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1648000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2121000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2431000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
105763000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
101393000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130714906 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130714906 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
130000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
131000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430072000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423386000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29178000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
101000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
us-gaap Gross Profit
GrossProfit
76378000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29679000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33282000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37240000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37587000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34044000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23509000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27708000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4208000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4965000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3972000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4600000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7486000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7888000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16023000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19820000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-360000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2169000 usd
us-gaap Profit Loss
ProfitLoss
-15663000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17651000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1600000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23084000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2800000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
dei Document Type
DocumentType
10-Q
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
37827000 usd
CY2023Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1438000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39265000 usd
dei Entity File Number
EntityFileNumber
001-40632
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
52634000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
392060000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15132000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44840000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
393064000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
491226000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Small Business
EntitySmallBusiness
false
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
115505000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
95111000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
55928000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
60877000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12514000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
390191000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18508000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18405000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10124000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10853000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
16183000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
16183000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4950000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3385000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51500000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142977000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
27178000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9882000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11171000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12429000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10942000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10351000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3091000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1208000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4405000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2235000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
157000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4185000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-784000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2271000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
941000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-6456000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15663000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.12
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
128810614 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
162272000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167299000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
31000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
331000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
46800000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12949000 usd
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
30487000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20492000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23084000 usd
CY2024Q3 us-gaap Assets
Assets
491226000 usd
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129766011 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
129766011 shares
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1275000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
385463000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
494457000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48000000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22495000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20822000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
65523000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58404000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
29005000 usd
us-gaap Gross Profit
GrossProfit
77454000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12076000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33217000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
33253000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
33598000 usd
us-gaap Operating Expenses
OperatingExpenses
100963000 usd
us-gaap Operating Expenses
OperatingExpenses
104086000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4248000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6420000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
119000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
595000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
694000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1677000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1433000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1622000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
941000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
941000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6456000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6456000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15663000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.01
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.05
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131003744 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136173278 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131121301 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135862905 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132785552 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136173278 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131121301 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135862905 shares
CY2024Q3 us-gaap Profit Loss
ProfitLoss
941000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-6456000 usd
us-gaap Profit Loss
ProfitLoss
-15663000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
101000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
165000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1232000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-856000 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
195000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
15000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
144000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-26000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1237000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6276000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14287000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18533000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
393064000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
506000 usd
CY2024Q1 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
148000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5640000 usd
CY2024Q1 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
-35000 usd
CY2024Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-244000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6169000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
392614000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
225000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1007000 usd
CY2024Q2 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
130000 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2670000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7152000 usd
CY2024Q2 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
-16000 usd
CY2024Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
1375000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10434000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
389123000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
146000 usd
CY2024Q3 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
146000 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11950000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7053000 usd
CY2024Q3 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
195000 usd
CY2024Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
101000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
941000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
385463000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
425546000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
204000 usd
CY2023Q1 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
57000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4699000 usd
CY2023Q1 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
152000 usd
CY2023Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-42000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6807000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
235000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
423460000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
483000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
966000 usd
CY2023Q2 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
111000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
981000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5922000 usd
CY2023Q2 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
-192000 usd
CY2023Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-980000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4388000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
424179000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
440000 usd
CY2023Q3 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
149000 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
8428000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5758000 usd
CY2023Q3 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
15000 usd
CY2023Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
165000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6456000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
415524000 usd
us-gaap Profit Loss
ProfitLoss
-15663000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5358000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4417000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2391000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2388000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19845000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
16379000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-52000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-73000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
55000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1378000 usd
us-gaap Inventory Write Down
InventoryWriteDown
798000 usd
ctkb Loss Gain On Investments Accretion And Amortization Net
LossGainOnInvestmentsAccretionAndAmortizationNet
-3631000 usd
ctkb Loss Gain On Investments Accretion And Amortization Net
LossGainOnInvestmentsAccretionAndAmortizationNet
-5265000 usd
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
512000 usd
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
1311000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3901000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7595000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12755000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2047000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2067000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2336000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2324000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3755000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
610000 usd
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
11000 usd
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
-374000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2300000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2154000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2344000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7216000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23382000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4231000 usd
ctkb Purchases Of Marketable Securities
PurchasesOfMarketableSecurities
-166812000 usd
ctkb Purchases Of Marketable Securities
PurchasesOfMarketableSecurities
-152563000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
150000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
78000000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
97000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2631000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3148000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
44896000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
195000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
118000 usd
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
0 usd
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
235000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19541000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122960000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
418000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
425000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1007000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
966000 usd
ctkb Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
424000 usd
ctkb Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
317000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
877000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1127000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1396000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
14620000 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
9409000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-12182000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8058000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3014000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-622000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5327000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-135871000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167630000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299500000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162303000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163629000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1922000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
810000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
99000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
96000 usd
ctkb Intangible Asset In Accrued Expense
IntangibleAssetInAccruedExpense
0 usd
ctkb Intangible Asset In Accrued Expense
IntangibleAssetInAccruedExpense
9000 usd
ctkb Derecognition In Operating Lease Right Of Use Asset
DerecognitionInOperatingLeaseRightOfUseAsset
-205000 usd
ctkb Derecognition In Operating Lease Right Of Use Asset
DerecognitionInOperatingLeaseRightOfUseAsset
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1637000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of business <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” or “FSP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” technology). The Company's goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has successfully developed and manufactured its full spectrum flow cytometry platform (“instrument(s)” or “product(s)”). The Company's core FSP instruments, the Cytek Aurora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Northern Lights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> systems, deliver high-resolution, high-content and high-sensitivity cell analysis. The Company also launched its Cytek Aurora cell sorter (“Aurora CS”), which leverages FSP technology to further broaden potential applications across cell analysis. The Company’s FSP platform includes instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company completed the acquisition of certain assets (the “FCI Acquisition”) relating to the flow cytometry and imaging business of Luminex Corporation (“Luminex”), including relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Guava</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">branded instruments, and flow cytometry reagent products and services (the “FCI Business”). The acquired FCI Business includes conventional flow and image-based flow cytometry instrumentation and related products and services (the “FCI Products”).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the state of Delaware in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div>The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited interim consolidated financial statements and accompanying notes as of the date of the unaudited interim consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.
CY2024Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2024Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162300000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167600000 usd
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Cash
Cash
35617000 usd
CY2023Q4 us-gaap Cash
Cash
22407000 usd
CY2024Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
2081000 usd
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
0 usd
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
124574000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
144892000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
31000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
331000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162303000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167630000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
300000 usd
CY2023Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
300000 usd
CY2024Q3 ctkb Number Of Bank Guarantees
NumberOfBankGuarantees
2 bank
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
30816 usd
CY2024Q3 ctkb Number Of Customers
NumberOfCustomers
2 customer
CY2024Q3 ctkb Security Warranty Obligation Term
SecurityWarrantyObligationTerm
P12M
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
372000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
197000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
126000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
301000 usd
ctkb Upfront And Payment Terms
UpfrontAndPaymentTerms
P30D
CY2024Q3 us-gaap Product Warranty Obligation Term
ProductWarrantyObligationTerm
P1Y
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
800000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3000000.0 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
500000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2700000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51500000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142977000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51500000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142977000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
40152000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
52634000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
55928000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
40152000 usd
CY2024Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1341000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41493000 usd
CY2022Q4 ctkb Contract With Customer Liability Revenue Recognized Excluding Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance
27665000 usd
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
36298000 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
47898000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39265000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
34735000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36963000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41493000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
26805000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
35718000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6138000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10454000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13857000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
14705000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
46800000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
60877000 usd
CY2024Q3 ctkb Prepaid Inventory
PrepaidInventory
56000 usd
CY2023Q4 ctkb Prepaid Inventory
PrepaidInventory
292000 usd
CY2024Q3 us-gaap Prepaid Rent
PrepaidRent
51000 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
255000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
769000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
990000 usd
CY2024Q3 us-gaap Prepaid Taxes
PrepaidTaxes
7384000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
5813000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2326000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2742000 usd
CY2024Q3 ctkb Tax Refund Receivable And Payable
TaxRefundReceivableAndPayable
22000 usd
CY2023Q4 ctkb Tax Refund Receivable And Payable
TaxRefundReceivableAndPayable
192000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2341000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2230000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12949000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12514000 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
14170000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
13748000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
759000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
665000 usd
CY2024Q3 ctkb Accrued Purchases
AccruedPurchases
2355000 usd
CY2023Q4 ctkb Accrued Purchases
AccruedPurchases
1871000 usd
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1955000 usd
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2805000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1494000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
946000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20733000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20035000 usd
CY2024Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1341000 usd
CY2023Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1438000 usd
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
396000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1297000 usd
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1342000 usd
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1763000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3529000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2444000 usd
CY2024Q3 us-gaap Long Term Construction Loan Current
LongTermConstructionLoanCurrent
1997000 usd
CY2023Q4 us-gaap Long Term Construction Loan Current
LongTermConstructionLoanCurrent
565000 usd
CY2024Q3 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
209000 usd
CY2023Q4 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
396000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8814000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7903000 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
242160000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
240003000 usd
CY2024Q3 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
115375000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
135000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000 usd
CY2024Q3 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
115505000 usd
CY2024Q3 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
115375000 usd
CY2024Q3 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
115505000 usd
CY2023Q4 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
95124000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
32000 usd
CY2023Q4 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
95111000 usd
CY2023Q4 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
95124000 usd
CY2023Q4 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
95111000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26532000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24325000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8024000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5920000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18508000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18405000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
2600000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
2000000.0 usd
CY2023Q1 ctkb Aggregate Cash Consideration
AggregateCashConsideration
44900000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
27892000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
27697000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7400000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4613000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20492000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 usd
CY2020Q4 ctkb Upfront Payment
UpfrontPayment
2000000 usd
CY2020Q4 ctkb Royalty Payment Duration
RoyaltyPaymentDuration
P10Y
CY2020Q4 ctkb Mile Stone Payment
MileStonePayment
6000000 usd
CY2024Q3 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
100000 usd
us-gaap Litigation Settlement Interest
LitigationSettlementInterest
500000 usd
CY2023Q3 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
500000 usd
us-gaap Litigation Settlement Interest
LitigationSettlementInterest
1300000 usd
CY2024Q3 ctkb Settlement Liabilities Payment Period
SettlementLiabilitiesPaymentPeriod
P10Y
us-gaap Revenues
Revenues
134782000 usd
CY2024Q3 us-gaap Noncurrent Assets
NoncurrentAssets
18507000 usd
CY2023Q4 us-gaap Noncurrent Assets
NoncurrentAssets
18405000 usd
CY2024Q3 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
2496000 usd
CY2023Q4 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
2561000 usd
CY2024Q3 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
17066000 usd
CY2023Q4 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
16477000 usd
CY2024Q3 ctkb Legal Settlement Liability
LegalSettlementLiability
19562000 usd
CY2023Q4 ctkb Legal Settlement Liability
LegalSettlementLiability
19038000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 ctkb Number Of Vote Per Share
NumberOfVotePerShare
1 vote
CY2023Q2 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000 usd
CY2023Q4 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
5332769 shares
CY2023Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34600000 usd
CY2023Q4 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
6.49
CY2023 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
6613780 shares
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
44000000 usd
CY2023 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
6.66
CY2023 ctkb Stock Repurchase Program Commission Costs
StockRepurchaseProgramCommissionCosts
100000 usd
CY2023 ctkb Stock Repurchase Program Commission Costs
StockRepurchaseProgramCommissionCosts
100000 usd
CY2024Q2 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000 usd
CY2024Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2194355 shares
CY2024Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
11900000 usd
CY2024Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
5.41
CY2024Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
35400000 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
9252454 shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
58600000 usd
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
6.33
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
300000 usd
CY2024Q3 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
400000 usd
CY2024Q3 ctkb Number Of Stock Based Compensation Plan
NumberOfStockBasedCompensationPlan
3 plan
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7219702 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.74
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23574000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1916670 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
560505 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
315297 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.54
ctkb Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
141740 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.79
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8118830 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M13D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9844000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5279627 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.24
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M28D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9771000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.64
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7053000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5758000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19845000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16379000 usd
CY2024Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
433036 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1417061 usd
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
469000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1238000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.021
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.110
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-784000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2271000 usd
CY2024Q3 ctkb Income Tax Expense Benefit Increase Decrease
IncomeTaxExpenseBenefitIncreaseDecrease
-3055000 usd
CY2024Q3 ctkb Income Tax Expense Benefit Increase Decrease Percent
IncomeTaxExpenseBenefitIncreaseDecreasePercent
-1.35
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-360000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2169000 usd
ctkb Income Tax Expense Benefit Increase Decrease
IncomeTaxExpenseBenefitIncreaseDecrease
1809000 usd
ctkb Income Tax Expense Benefit Increase Decrease Percent
IncomeTaxExpenseBenefitIncreaseDecreasePercent
-0.83
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2300000 usd
CY2024Q3 ctkb Income Tax Expense Benefit Increase Decrease
IncomeTaxExpenseBenefitIncreaseDecrease
-3100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2200000 usd
ctkb Income Tax Expense Benefit Increase Decrease
IncomeTaxExpenseBenefitIncreaseDecrease
1800000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2390000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2388000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
580000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
639000 usd
us-gaap Lease Cost
LeaseCost
2970000 usd
us-gaap Lease Cost
LeaseCost
3027000 usd
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
0 usd
us-gaap Sublease Income
SubleaseIncome
57000 usd
ctkb Operating Cash Outflows Payments On Operating Leases
OperatingCashOutflowsPaymentsOnOperatingLeases
2495000 usd
ctkb Operating Cash Outflows Payments On Operating Leases
OperatingCashOutflowsPaymentsOnOperatingLeases
2412000 usd
ctkb Right Of Use Assets Obtained In Exchange For New Lease Obligations
RightOfUseAssetsObtainedInExchangeForNewLeaseObligations
1637000 usd
ctkb Right Of Use Assets Obtained In Exchange For New Lease Obligations
RightOfUseAssetsObtainedInExchangeForNewLeaseObligations
0 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10124000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10853000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3529000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2444000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7756000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9479000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11285000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11923000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M23D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M4D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.031
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.027
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
913000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3659000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2504000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2315000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2047000 usd
CY2024Q3 ctkb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
348000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11786000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
501000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11285000 usd
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
477000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
2125000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
1969000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
902000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
5473000 usd
CY2021Q1 ctkb Noncontrolling Interest In Consolidated Subsidiary
NoncontrollingInterestInConsolidatedSubsidiary
315000 usd
CY2023Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2805000 usd
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2126000 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
797000 usd
CY2023 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
3540000 usd
us-gaap Product Warranty Expense
ProductWarrantyExpense
1648000 usd
CY2023 us-gaap Product Warranty Expense
ProductWarrantyExpense
2861000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1954000 usd
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2805000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
941000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-6456000 usd
us-gaap Profit Loss
ProfitLoss
-15663000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
941000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
941000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6456000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6456000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15663000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15663000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17651000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131003744 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136173278 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131121301 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135862905 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1781808 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132785552 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136173278 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131121301 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135862905 shares
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.12
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.05
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131003744 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6200000 shares
CY2024Q3 us-gaap Revenues
Revenues
51500000 usd
CY2023Q3 us-gaap Revenues
Revenues
48000000 usd
us-gaap Revenues
Revenues
142977000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001628280-24-045834-index-headers.html Edgar Link pending
0001628280-24-045834-index.html Edgar Link pending
0001628280-24-045834.txt Edgar Link pending
0001628280-24-045834-xbrl.zip Edgar Link pending
ctkb-20240930.htm Edgar Link pending
ctkb-20240930.xsd Edgar Link pending
ctkb-20240930exx311.htm Edgar Link pending
ctkb-20240930exx312.htm Edgar Link pending
ctkb-20240930exx321.htm Edgar Link pending
ctkb-20240930exx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
ctkb-20240930_def.xml Edgar Link unprocessable
ctkb-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctkb-20240930_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ctkb-20240930_pre.xml Edgar Link unprocessable
ctkb-20240930_cal.xml Edgar Link unprocessable